Th17/Treg细胞在慢性乙型肝炎发病机制及临床转归中的作用

doi:10.3969/j.issn.1672-5069.2011.05.035

摘要/Abstract

摘要： Thl7和Treg细胞具有共同的起源，抑制ThI7细胞产生可以促进Treg细胞的发育。本文就Th17/Treg细胞的相互关系，以及在慢性乙型肝炎发病机制和临床转归中的作用进行了综述和展望。

殷杰,徐栋花,冯灏. Th17/Treg细胞在慢性乙型肝炎发病机制及临床转归中的作用[J]. 实用肝脏病杂志, 2011, 14(5): 389-392.

[1] BERTOLETTI A，MAINIMK，FERRARI C. The host-pathogen interaction during HBV infection:immunological controversies[J].Antivir Ther，2010，15 （Suppl 3）:15-24.
[2] MIROUX C，VAUSSELIN T，DELHEM N. Regulatory T cells in HBV and HCV liver diseases:implication of regulatory T lymphocytes in the control of immune response[J]. Expert Opin Biol Ther，2010，10（11）:1563-1572.
[3] FISICARO P，VALDATTA C，BONI C，et al． Early kinetics of innate and adaptive immune responses during hepatitis B virus infection[J]. Gut，2009，58（7）:974-982.
[4] INFANTE D，HORTON HF，BYRNE MC，et al． Microbial lipopeptides induce the production of IL-17 in Th cells[J]． J Immunol，2000，165（11）:6107-6115．
[5] PARK H，LI Z，YANG XO，et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol，2005，6（11）:1133-1141.
[6] LVANOV II，MCKENZIE BS，ZHOU L，et a1． The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+T helper cells[J]. Cell，2006，126（6）:1121-1133．
[7] MANGAN PR，HARRINGTON LE，O'QUINN DB，et al． Transforming growth factor-beta induces development of the THl7 lineage[J]． Nature，2006，441（7090）:231-234．
[8] STOCKINGER B，VELDHOEN M． Differentiation and function of Thl7 T cells[J]． Curt Opin Immunol，2007，19（3）:281-286．
[9] KORN T，BETTELLI E，OUKKA M，et al. IL-17 and Th17 Cells[J]. Annu Rev Immunol，2009，27:485-517.
[10] SUTTON C，BRERETON C，KEOGH B，et al． A crucial role for interleukin（IL）-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis[J]. J Exp Med，2006，203（7）:1685-1691．
[11] CHEN Z，LAURENCE A，KANNO Y，et al． Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells [J]． Proc Natl Acad Sci USA，2006，103（21）:8137-8142.
[12] BATTEN M，LI J，YI S，et al． Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells[J]． Nat Rev lmmunol，2006，7（9）:929-936．
[13] GAFFEN SL. Structure and signaling in the IL-17 receptor family[J]. Nat Rev Immunol，2009，9（8）:556-567.
[14] STEINMAN L. A brief history of TH17，the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage[J]. Nat Med，2007，13（2）:139-145.
[15] DIAZ JA，BOOTH AJ，LU G，et al. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection[J]. Am J Transplant，2009，9（8）:1773-1783.
[16] LUBBERTS E，KOENDERS MI，VANDER BW． The role of T cell interleukin-17 in conducting destructive arthritis：lessons from animal models[J]． Arthritis Res，2005，7（1）:29-37．
[17] BETTELLI E，KORN T，OUKKA M，et al. Induction and effector functions of TH17 cells[J]. Nature，2008，453（7198）:1051-1057.
[18] FAUST SM，LU G，MARINI BL，et al. Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection[J]. J Immunol，2009，183（11）:7297-7306.
[19] WILSON MS，MADALA SK，RAMALINGAM TR，et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent[J]. J Exp Med，2010，207（3）:535-552.
[20] ZUBER J，BRODIN-SARTORIUS A，LAPIDUS N，et al. FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis[J]. Nephrol Dial Transplant，2009，24（12）:3847-3854.
[21] ZHANG JY，ZHANG Z，LIN F，et al. Interleukin-17-producing CD4+T cells increase with severity of liver damage in patients with chronic hepatitis B[J]. Hepatology，2010，51（1）:81-91.
[22] VELDHOEN M，HOCKING RJ，ATKINS CJ，et al． TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J]. Immunity，2006，24（2）:179-189．
[23] KOLLS JK，LINDN A. Interleukin-17 family members and inflammation [J]． Immunity，2004，21（4）:467-476．
[24] LEMMERS A，MORENO C，GUSTOT T，et al． The Interleukin-17 Pathway Is Involved in Human Alcoholic Liver Disease[J]．Hepatology，2009，49（2）:646-657．
[25] RONG G，ZHOU Y，XIONG Y，et al． Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis：the serum cytokine profile and peripheral cell population[J]． Clin Exp Immunol，2009，156（2）:217-225．
[26] SAKAGUCHI S．Regulatory T cells：key controllers of immunologic self-tolerance[J]． Cell，2000，101（5）:455-458．
[27] B1UESTONE JA，ABBAS AK． Natural Versus adaptive regulatory T cells[J]． Nat Rev Immunol，2003，3（3）:253-257．
[28] SAKAGUCHI S. Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self[J]. Nat Immunol，2005，6（4）:345-352．
[29] LIU W，PUTNAM AL，XU-YU Z，et al． CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells[J]． J Exp Med，2006，203（7）:1701-1711．
[30] LAURENCE A，TATO CM，DAVIDSON TS，et al． Interleukin-2 signaling via STAT5 contains T helper 17 cell generation[J]．Immunity，2007，26（3）:371-381．
[31] XU D，FU J，JIN L，et al． Circulating and 1iver resident CD4+CD25+regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J]． J Immunol，2006，177（1）:739-747．
[32] LAN RY，CHENG C，LIAN ZX，et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis[J]. Hepatology，2006，43（4）:729-737.
[33] ORMANDY LA，HILLEMANN T，WEDEMEYER H，et al． Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J]. Cancer Res，2005，65（6）:2457-2464．
[34] STOOP JN，VAN DER MOLEN RG，KUIPERS EJ，et al． Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B[J].Virology，2007，361（1）:141-148．
[35] YOU J，HUANG L，ZHANG YF，et al. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load[J]. World J Gastroenterol，2009，15（27）:3382-3339.
[36] STOOPJN，WOLTMAN AM，BIESTA PJ，et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response[J]． Hepatology，2007，46（3）:699-705．
[37] CHEN MT，BILLAUD JN，SALLBERG M，et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen[J]. Proc Natl Acad Sci USA，2004，101（41）:14913-14918.
[38] ZHANG JY，SONG CH，SHI F，et al. Decreased Ratio of Treg Cells to Th17 Cells Correlates with HBV DNA Suppression in Chronic Hepatitis B Patients Undergoing Entecavir Treatment[J]. Plos One，2010，5:e13869.
[39] ROMAGNANI S.Human Thl7 cells[J]. Arthritis Res Ther，2008，10（2）:206.
[40] HANIDZIAR D，KOULMANDA M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance[J]. Curr Opin Organ Transplant，2010，15（4）:411-415.
[41] TSAI HT，TSAI TH，LU TM，et al． Immunopathology of hepatitis B virus infection[J]． Int Rev Immunol，2008，27（6）:427-446．
[42] SPRENGERS D，STOOP JN，BINDA RS，et al. Induction of regulatory T-cells and interleukin-10-producing cells in nonresponders to pegylated interferon-alpha therapy for chronic hepatitis B[J]. Antivir Ther，2007，12（7）:1087-1096.
[43] STOOP JN，VAN DER MOLEN RG，BAAN CC，et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J]. Hepatology，2005，41（4）:771-778.

Th17/Treg细胞在慢性乙型肝炎发病机制及临床转归中的作用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.